CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 40 enrolled
Drug / intervention
Cannabidiol +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05388058
NCT05388058Phase 2Completed

Topical Cannabidiol (CBD) for the Treatment of Chemotherapy-Induced Peripheral Neuropathy: A Randomized Placebo-Controlled Pilot Trial

Mayo Clinic·interventional·Posted May 24, 2022·Updated Jan 16, 2026

In Brief

A Phase 2 clinical trial evaluating Cannabidiol, Placebo Administration, and 2 other interventions for Chemotherapy-Induced Peripheral Neuropathy and Malignant Solid Neoplasm. Completed, enrolled 40 participants across 9 sites.

Detailed Summary

This clinical trial compares topical cannabidiol to placebo in improving chemotherapy-induced peripheral neuropathy, or painful sensations in your hands or feet due to chemotherapy. Peripheral neuropathy is a nerve problem that causes pain, numbness, tingling, swelling, or muscle weakness in different parts of the body. It usually begins in the hands or feet and gets worse over time. Peripheral neuropathy caused by chemotherapy is called chemotherapy-induced peripheral neuropathy (CIPN). CIPN is commonly seen in patients receiving certain chemotherapy medications and is hard to treat. Medications commonly used to treat CIPN have limited benefits and may cause significant side effects. A small report showed that topical cannabidiol may help treat neuropathy in patients with diabetes. This study is being done to determine if cannabidiol cream can help improve the symptoms of CIPN.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedMay 24, 2022
Enrollment StartJun 9, 2022
Primary CompletionJul 14, 2023
Study CompletionJul 28, 2023
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 4.1 years ago

Interventions

Cannabidioldrug

Applied topically

Placebo Administrationdrug

Applied topically

Quality-of-Life Assessmentother

Ancillary studies

Questionnaire Administrationother

Ancillary studies